A Phase 1/2 interventional study of Nivolumab and Daratumumab in Advanced Cancer, sponsored by Bristol-Myers Squibb. Completed at 20 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-07-23.
Sponsored by Bristol-Myers Squibb · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 120 studies testing nivolumab in Carcinoma, Non-Small-Cell Lung — 22 open to participants now, 44 under way, 6 of them phase 3. Nivolumab · Carcinoma, Non-Small-Cell Lung.
Among the 120 studies testing nivolumab in Carcinoma, Non-Small-Cell Lung, this one is the 39th largest by enrollment, is one of 24 that started in 2017, is one of 12 in phase 1/2, and was the 42nd registered.
7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,837 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →22 of the 120 studies testing nivolumab in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:
University of Chicago · Sites in United States
Ages 18+
Washington University School of Medicine · Sites in United States
Ages 18+
Liza Villaruz, MD · Sites in United States
Ages 18+
Diwakar Davar · Sites in United States
Ages 18+
EuroCityClinic LLC · Sites in Russia
Ages 18+
By country, each count listing its studies:
Nivolumab: first FDA approval 2014 (OPDIVO), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, nivolumab is the treatment under test here. Read study by study →
120 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 27 · Phase 2 78 · Phase 3 24 · Phase 4 2
First in 2006; this study’s year is marked. 24 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 105 is above the median of 62 across 6,023 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 66 across the 120 interventional studies. Of the 62 that completed or were terminated, 44 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
36 of 120 have an industry lead sponsor. The 10 most frequent:
Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
131 studies in Carcinoma, Non-Small-Cell Lung by Bristol-Myers Squibb: 21 open now, 35 under way, 10 of them phase 3. Of 91 finished, 47 (52%) have results posted.
Among the 131 studies in Carcinoma, Non-Small-Cell Lung by Bristol-Myers Squibb, this one is the 63rd largest by enrollment of the 107 interventional ones that give a count, is one of 9 that started in 2017, is one of 19 in phase 1/2, and was the 62nd registered.
Bristol-Myers Squibb’s Carcinoma, Non-Small-Cell Lung studies by the year they started, since 2000.
13 of the studies testing nivolumab in Carcinoma, Non-Small-Cell Lung that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02595944Phase 3National Cancer Institute (NCI)Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer (An ALCHEMIST Treatment Trial) | 2027-05-31 |
| NCT03527108Fox Chase Cancer CenterNivolumab Plus Ramucirumab in Patients With Recurrent, Advanced, Metastatic NSCLC | 2026-12 |
| NCT05597800Universita di VeronaNivolumab/Ipilimumab and Chemotherapy Combination in Advanced NSCLC Patients With HIV, HBV, HCV and Long Covid Syndrome | 2026-12-31 |
| NCT06946797Bristol-Myers SquibbA Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC) | 2027-02-05 |
| NCT06275360VA Office of Research and DevelopmentRepositioning Immunotherapy in VetArans With Lung Cancer | 2027-02-28 |
Add all 13 to your calendar (.ics) → With an account.
Among the 120 studies testing nivolumab in Carcinoma, Non-Small-Cell Lung, from their registry updates:
Among Bristol-Myers Squibb’s 131 in Carcinoma, Non-Small-Cell Lung:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine whether a combination of Nivolumab and Daratumumab is safe and effective when treating Pancreatic, Non-Small Cell Lung or Triple Negative Breast Cancers, that have advanced or have spread.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com
Exclusion Criteria:
Other protocol defined inclusion/exclusion criteria could apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TNBC and PAC participants who are deriving clinical benefit will continue to be treated with the nivolumab plus daratumumab combination therapy
Biological: Nivolumab · Biological: Daratumumab
NSCLC patients who are deriving clinical benefit will be treated with nivolumab monotherapy
Biological: Nivolumab
Specified dose on specified days
Specified dose on specified days
Number of Participants With Adverse Events (AEs)
Number of participants with any grade of adverse events (AEs) graded by Common Terminology Criteria for Adverse Events (CTCAE v4.0) to determine the safety and tolerability of Nivolumab and Daratumumab
Time frame: From first dose to 30 days post last dose (up to 34 months)
Number of Participants With Serious Adverse Events (SAEs)
Number of participants with any grade of serious adverse events (SAEs) graded by Common Terminology Criteria for Adverse Events (CTCAE v4.0) to determine the safety and tolerability of Nivolumab and Daratumumab
Time frame: From first dose to 30 days post last dose (up to 34 months)
Number of Participants With Laboratory Abnormalities in Specific Liver Tests
Number of participants with laboratory abnormalities in specific liver tests based on US conventional units to determine the safety and tolerability of Nivolumab and Daratumumab. The number of participants with the following laboratory abnormalities from on-treatment evaluations will be summarized: * ALT or AST \> 3 x ULN, \> 5 x ULN, \> 10 x ULN and \> 20 x ULN * Total bilirubin \> 2 x ULN * ALP \> 1.5 x ULN * Concurrent (within 1 day) ALT or AST \> 3 x ULN and total bilirubin \> 1.5 x ULN * Concurrent (within 30 days) ALT or AST \> 3 x ULN and total bilirubin \> 1.5 x ULN * Concurrent (within 1 day) ALT or AST \> 3 x ULN and total bilirubin \> 2 x ULN * Concurrent (within 30 days) ALT or AST \> 3 x ULN and total bilirubin \> 2 x ULN
Time frame: From first dose to 30 days post last dose (up to 34 months)
Number of Participants With Laboratory Abnormalities in Specific Thyroid Tests
Number of participants with laboratory abnormalities in specific thyroid tests based on US conventional units to determine the safety and tolerability of Nivolumab and Daratumumab. The number of subjects with the following laboratory abnormalities from on-treatment evaluations will be summarized: * TSH value \> ULN and * with baseline TSH value \<= ULN * with at least one FT3/FT4 test value \< LLN within 2-week window after the abnormal TSH test * with all FT3/FT4 test values \>= LLN within 2-week window after the abnormal TSH test * with FT3/FT4 missing within 2-week window after the abnormal TSH test. * TSH \< LLN and * with baseline TSH value \>= LLN * with at least one FT3/FT4 test value \> ULN within 2-week window after the abnormal TSH test * with all FT3/FT4 test values \<= ULN within 2-week window after the abnormal TSH test * with FT3/FT4 missing within 2-week window after the abnormal TSH test
Time frame: From first dose to 30 days post last dose (up to 34 months)
Number of Participants With Laboratory Results of Worst CTC Grade
Number of participants with laboratory test results of worst (CTC v4.0) grades 0-4 to determine the safety and tolerability of Nivolumab and Daratumumab
Time frame: From first dose to 30 days post last dose (up to 34 months)
Objective Response Rate (ORR)
Objective response rate (ORR) is defined as the percentage of treated participants who achieve a best response of complete response (CR) or partial response (PR) based on investigator assessments (using RECIST v1.1 criteria)
Time frame: Up to 36 months
Duration of Response (DOR)
Duration of response (DOR) is defined as the time between the date of first documented response (Complete response or partial response) to the date of the first documented tumor progression as determined by Investigator (per RECIST v1.1 criteria), or death due to any cause, whichever occurs first
Time frame: Up to 36 months
Best Overall Response (BOR)
Best overall response (BOR) is defined as the best response, as determined by Investigator, recorded between the date of first dose and the date of objectively documented progression per RECIST v1.1 criteria or the date of subsequent therapy, whichever occurs first.
Time frame: Up to 36 months
Progression Free Survival (PFS)
Progression Free Survival (PFS) is defined as the time between the date of treatment start day and the date of first documented tumor progression, based on Investigator assessments (per RECIST v1.1 criteria), or death due to any cause, whichever occurs first.
Time frame: Up to 36 months
Nivolumab Serum Concentrations
Pharmacokinetics (PK) assessed using serum concentration data for Nivolumab
Time frame: From day 1 to follow-up 2 (up to 36 months)
Daratumumab Serum Concentrations
Pharmacokinetics (PK) assessed using serum concentration data for Daratumumab
Time frame: From day 1 to follow-up 2 (up to 36 months)
Percentage of Participants Anti Drug Antibody (ADA) by Positivity
Percentage of participants Anti Drug Antibody (ADA) to assess immunogenicity by ADA positive status and ADA negative status, relative to baseline. ADA positive is a participant with at least one ADA-positive sample relative to baseline (ADA negative at baseline or ADA titer to be at least 4-fold or greater (\>=) than baseline positive titer) at any time after initiation of treatment. ADA Negative is a participant with no ADA-positive sample after initiation of treatment
Time frame: Up to 36 months
| Milestone | Nivolumab + Daratumumab (TNBC) | Nivolumab + Daratumumab (NSCLC) | Nivolumab + Daratumumab (PAC) |
|---|---|---|---|
| Started | 41 | 21 | 43 |
| Completed | 0 | 1 | 0 |
| Not completed | 41 | 20 | 43 |
| Withdrew: Disease progression | 30 | 19 | 41 |
| Withdrew: Study drug toxicity | 2 | 1 | 0 |
| Withdrew: Death | 1 | 0 | 0 |
| Withdrew: Adverse event unrelated to study drug | 6 | 0 | 1 |
| Withdrew: Administrative reason by sponsor | 0 | 0 | 1 |
| Withdrew: Other reasons | 2 | 0 | 0 |
Number of participants with any grade of adverse events (AEs) graded by Common Terminology Criteria for Adverse Events (CTCAE v4.0) to determine the safety and tolerability of Nivolumab and Daratumumab
| Participants | Nivolumab + Daratumumab (TNBC) | Nivolumab + Daratumumab (NSCLC) | Nivolumab + Daratumumab (PAC) |
|---|---|---|---|
| Number of Participants With Adverse Events (AEs) | 41 | 21 | 42 |
Number of participants with any grade of serious adverse events (SAEs) graded by Common Terminology Criteria for Adverse Events (CTCAE v4.0) to determine the safety and tolerability of Nivolumab and Daratumumab
| Participants | Nivolumab + Daratumumab (TNBC) | Nivolumab + Daratumumab (NSCLC) | Nivolumab + Daratumumab (PAC) |
|---|---|---|---|
| Number of Participants With Serious Adverse Events (SAEs) | 29 | 14 | 29 |
Number of participants with laboratory abnormalities in specific liver tests based on US conventional units to determine the safety and tolerability of Nivolumab and Daratumumab. The number of participants with the following laboratory abnormalities from on-treatment evaluations will be summarized: * ALT or AST \> 3 x ULN, \> 5 x ULN, \> 10 x ULN and \> 20 x ULN * Total bilirubin \> 2 x ULN * ALP \> 1.5 x ULN * Concurrent (within 1 day) ALT or AST \> 3 x ULN and total bilirubin \> 1.5 x ULN * Concurrent (within 30 days) ALT or AST \> 3 x ULN and total bilirubin \> 1.5 x ULN * Concurrent (within 1 day) ALT or AST \> 3 x ULN and total bilirubin \> 2 x ULN * Concurrent (within 30 days) ALT or AST \> 3 x ULN and total bilirubin \> 2 x ULN
| Participants | Nivolumab + Daratumumab (TNBC) | Nivolumab + Daratumumab (NSCLC) | Nivolumab + Daratumumab (PAC) |
|---|---|---|---|
| ALT OR AST > 3XULN | 6 | 2 | 10 |
| ALT OR AST > 5XULN | 5 | 2 | 6 |
| ALT OR AST > 10XULN | 2 | 1 | 3 |
| ALT OR AST > 20XULN | 0 | 0 | 0 |
| TOTAL BILIRUBIN > 2XULN | 1 | 1 | 8 |
| ALP > 1.5XULN | 10 | 5 | 34 |
| CONCURRENT ALT OR AST ELEVATION > 3XULN WITH TOTAL BILIRUBIN > 1.5XULN WITHIN ONE DAY | 1 | 1 | 5 |
| CONCURRENT ALT OR AST ELEVATION > 3XULN WITH TOTAL BILIRUBIN > 1.5XULN WITHIN 30 DAYS | 1 | 1 | 5 |
| CONCURRENT ALT OR AST ELEVATION > 3XULN WITH TOTAL BILIRUBIN > 2XULN WITHIN ONE DAY | 1 | 1 | 5 |
| CONCURRENT ALT OR AST ELEVATION > 3XULN WITH TOTAL BILIRUBIN > 2XULN WITHIN 30 DAYS | 1 | 1 | 5 |
Number of participants with laboratory abnormalities in specific thyroid tests based on US conventional units to determine the safety and tolerability of Nivolumab and Daratumumab. The number of subjects with the following laboratory abnormalities from on-treatment evaluations will be summarized: * TSH value \> ULN and * with baseline TSH value \<= ULN * with at least one FT3/FT4 test value \< LLN within 2-week window after the abnormal TSH test * with all FT3/FT4 test values \>= LLN within 2-week window after the abnormal TSH test * with FT3/FT4 missing within 2-week window after the abnormal TSH test. * TSH \< LLN and * with baseline TSH value \>= LLN * with at least one FT3/FT4 test value \> ULN within 2-week window after the abnormal TSH test * with all FT3/FT4 test values \<= ULN within 2-week window after the abnormal TSH test * with FT3/FT4 missing within 2-week window after the abnormal TSH test
| Participants | Nivolumab + Daratumumab (TNBC) | Nivolumab + Daratumumab (NSCLC) | Nivolumab + Daratumumab (PAC) |
|---|---|---|---|
| TSH > ULN | 4 | 3 | 4 |
| TSH > ULN WITH TSH <= ULN AT BASELINE | 4 | 3 | 2 |
| TSH > ULN WITH AT LEAST ONE FT3/FT4 TEST VALUE < LLN | 1 | 1 | 3 |
| TSH > ULN WITH ALL OTHER FT3/FT4 TEST VALUES >= LLN | 2 | 2 | 0 |
| TSH > ULN WITH FT3/FT4 TEST MISSING | 1 | 0 | 1 |
| TSH < LLN | 1 | 2 | 2 |
| TSH < LLN WITH TSH >= LLN AT BASELINE | 1 | 2 | 1 |
| TSH < LLN WITH AT LEAST ONE FT3/FT4 TEST VALUE > ULN | 1 | 0 | 0 |
| TSH < LLN WITH ALL OTHER FT3/FT4 TEST VALUES <= ULN | 0 | 2 | 1 |
| TSH < LLN WITH FT3/FT4 TEST MISSING | 0 | 0 | 1 |
Objective response rate (ORR) is defined as the percentage of treated participants who achieve a best response of complete response (CR) or partial response (PR) based on investigator assessments (using RECIST v1.1 criteria)
| Percentage of Participants | Nivolumab + Daratumumab (TNBC) | Nivolumab + Daratumumab (NSCLC) | Nivolumab + Daratumumab (PAC) |
|---|---|---|---|
| Objective Response Rate (ORR) | 4.9 (0.6 to 16.5) | 9.5 (1.2 to 30.4) | 0 (0.0 to 8.2) |
Duration of response (DOR) is defined as the time between the date of first documented response (Complete response or partial response) to the date of the first documented tumor progression as determined by Investigator (per RECIST v1.1 criteria), or death due to any cause, whichever occurs first
| Months | Nivolumab + Daratumumab (TNBC) | Nivolumab + Daratumumab (NSCLC) | Nivolumab + Daratumumab (PAC) |
|---|---|---|---|
| Duration of Response (DOR) | 4.17 (NA to NA) | 9.40 (7.72 to 11.07) | — |
Best overall response (BOR) is defined as the best response, as determined by Investigator, recorded between the date of first dose and the date of objectively documented progression per RECIST v1.1 criteria or the date of subsequent therapy, whichever occurs first.
| Participants | Nivolumab + Daratumumab (TNBC) | Nivolumab + Daratumumab (NSCLC) | Nivolumab + Daratumumab (PAC) |
|---|---|---|---|
| Complete Response (CR) | 0 | 0 | 0 |
| Partial Response (PR) | 2 | 2 | 0 |
| Stable Disease (SD) | 8 | 10 | 9 |
| Progressive Disease (PD) | 22 | 9 | 31 |
| Unable to Determine (UTD) | 9 | 0 | 3 |
Progression Free Survival (PFS) is defined as the time between the date of treatment start day and the date of first documented tumor progression, based on Investigator assessments (per RECIST v1.1 criteria), or death due to any cause, whichever occurs first.
| Months | Nivolumab + Daratumumab (TNBC) | Nivolumab + Daratumumab (NSCLC) | Nivolumab + Daratumumab (PAC) |
|---|---|---|---|
| Progression Free Survival (PFS) | 1.22 (1.15 to 1.41) | 4.85 (1.12 to 7.69) | 1.22 (1.15 to 1.38) |
Pharmacokinetics (PK) assessed using serum concentration data for Nivolumab
| µg/mL | Nivolumab + Daratumumab (TNBC) | Nivolumab (NSCLC) | Nivolumab (PAC) |
|---|---|---|---|
| Cycle 3 Day 1 | 52.9 ± 34.8 | 43.5 ± 26.6 | 42.5 ± 29.7 |
| Cycle 4 Day 1 | 87.0 ± 34.0 | 77.9 ± 37.6 | 64.3 ± 31.4 |
| Cycle 7 Day 1 | 44.8 ± 32.8 | 116.2 ± 23.8 | 83.3 ± NA |
| Cycle 11 Day 1 | — | 124.3 ± 46.5 | — |
| Follow-up 1 | 48.9 ± 44.0 | 71.6 ± 58.9 | 32.8 ± 48.6 |
| Follow-up 2 | 23.5 ± 60.6 | 17.4 ± 96.1 | 6.3 ± 89.7 |
Pharmacokinetics (PK) assessed using serum concentration data for Daratumumab
| µg/mL | Nivolumab + Daratumumab (TNBC) | Daratumumab (NSCLC) | Daratumumab (PAC) |
|---|---|---|---|
| Cycle 1 Day 1 (hour 8) | 334.1819 ± 28.1 | 310.7272 ± 15.6 | 277.6708 ± 28.4 |
| Cycle 2 Day 1 (hour 0) | 332.9353 ± 29.6 | 321.6084 ± 25.7 | 275.1521 ± 35.9 |
| Cycle 2 Day 1 (hour 4) | 735.2131 ± 36.9 | 641.8146 ± 26.3 | 569.8158 ± 27.4 |
| Cycle 3 day 1 | 629.9607 ± 19.8 | 477.6488 ± 25.0 | 473.0335 ± 23.8 |
| Cycle 4 day 1 | 559.8988 ± 31.0 | 393.5442 ± 48.9 | 406.9487 ± 28.2 |
| Cycle 7 day 1 | 294.8322 ± NA | 515.2495 ± 21.9 | 229.0854 ± NA |
| Follow-up 1 | 177.5615 ± 65.0 | 157.5960 ± 62.2 | 184.1510 ± 51.7 |
| Follow-up 2 | 134.0478 ± NA | 57.3349 ± NA | 8.4517 ± 158.4 |
Percentage of participants Anti Drug Antibody (ADA) to assess immunogenicity by ADA positive status and ADA negative status, relative to baseline. ADA positive is a participant with at least one ADA-positive sample relative to baseline (ADA negative at baseline or ADA titer to be at least 4-fold or greater (\>=) than baseline positive titer) at any time after initiation of treatment. ADA Negative is a participant with no ADA-positive sample after initiation of treatment
| Percentage of Participants | Nivolumab + Daratumumab (TNBC) | Nivolumab + Daratumumab (NSCLC) | Nivolumab + Daratumumab (PAC) |
|---|---|---|---|
| Nivolumab Baseline ADA Positive | 0.00 | 6.3 | 0.00 |
| Daratumumab Baseline ADA Positive | 0.00 | 5.6 | 0.00 |
| Nivolumab ADA Positive | 0.00 | 0.00 | 0.00 |
| Nivolumab ADA Negative | 100.0 | 100.0 | 100.0 |
| Daratumumab ADA Positive | 0.00 | 0.00 | 0.00 |
| Daratumumab ADA Negative | 100.0 | 100.0 | 100.0 |
Number of participants with laboratory test results of worst (CTC v4.0) grades 0-4 to determine the safety and tolerability of Nivolumab and Daratumumab
| Participants | Nivolumab + Daratumumab (TNBC) | Nivolumab + Daratumumab (NSCLC) | Nivolumab + Daratumumab (PAC) |
|---|---|---|---|
| Hemoglobin — Grade 0 | 13 | 5 | 5 |
| Hemoglobin — Grade 1 | 14 | 9 | 23 |
| Hemoglobin — Grade 2 | 7 | 7 | 12 |
| Hemoglobin — Grade 3 | 5 | 0 | 3 |
| Hemoglobin — Grade 4 | NA | NA | NA |
| Hemoglobin — Not Reported | 2 | 0 | 0 |
| Platelet Count — Grade 0 | 29 | 16 | 24 |
| Platelet Count — Grade 1 | 4 | 4 | 18 |
| Platelet Count — Grade 2 | 0 | 0 | 0 |
| Platelet Count — Grade 3 | 1 | 1 | 1 |
| Platelet Count — Grade 4 | 5 | 0 | 0 |
| Platelet Count — Not Reported | 2 | 0 | 0 |
| Leukocytes — Grade 0 | 27 | 18 | 35 |
| Leukocytes — Grade 1 | 7 | 1 | 3 |
| Leukocytes — Grade 2 | 4 | 1 | 5 |
| Leukocytes — Grade 3 | 1 | 1 | 0 |
| Leukocytes — Grade 4 | 0 | 0 | 0 |
| Leukocytes — Not Reported | 2 | 0 | 0 |
| Alkaline Phosphatase — Grade 0 | 23 | 13 | 6 |
| Alkaline Phosphatase — Grade 1 | 7 | 4 | 11 |
| Alkaline Phosphatase — Grade 2 | 4 | 1 | 13 |
| Alkaline Phosphatase — Grade 3 | 2 | 3 | 13 |
| Alkaline Phosphatase — Grade 4 | 0 | 0 | 0 |
| Alkaline Phosphatase — Not Reported | 5 | 0 | 0 |
| Aspartate Aminotransferase — Grade 0 | 16 | 16 | 20 |
| Aspartate Aminotransferase — Grade 1 | 15 | 3 | 13 |
| Aspartate Aminotransferase — Grade 2 | 2 | 1 | 5 |
| Aspartate Aminotransferase — Grade 3 | 4 | 1 | 5 |
| Aspartate Aminotransferase — Grade 4 | 0 | 0 | 0 |
| Aspartate Aminotransferase — Not Reported | 4 | 0 | 0 |
| Alanine Aminotransferase — Grade 0 | 19 | 12 | 19 |
| Alanine Aminotransferase — Grade 1 | 15 | 6 | 19 |
| Alanine Aminotransferase — Grade 2 | 1 | 0 | 1 |
| Alanine Aminotransferase — Grade 3 | 2 | 2 | 4 |
| Alanine Aminotransferase — Grade 4 | 0 | 0 | 0 |
| Alanine Aminotransferase — Not Reported | 4 | 1 | 0 |
| Bilirubin — Grade 0 | 30 | 18 | 30 |
| Bilirubin — Grade 1 | 5 | 1 | 4 |
| Bilirubin — Grade 2 | 0 | 1 | 3 |
| Bilirubin — Grade 3 | 1 | 1 | 6 |
| Bilirubin — Grade 4 | 0 | 0 | 0 |
| Bilirubin — Not Reported | 5 | 0 | 0 |
| Creatinine — Grade 0 | 30 | 15 | 38 |
| Creatinine — Grade 1 | 5 | 5 | 4 |
| Creatinine — Grade 2 | 1 | 1 | 0 |
| Creatinine — Grade 3 | 0 | 0 | 0 |
| Creatinine — Grade 4 | 0 | 0 | 0 |
| Creatinine — Not Reported | 5 | 0 | 1 |
| Phosphorous — Grade 0 | 29 | 15 | 33 |
| Phosphorous — Grade 1 | 0 | 0 | 2 |
| Phosphorous — Grade 2 | 4 | 5 | 4 |
| Phosphorous — Grade 3 | 2 | 1 | 3 |
| Phosphorous — Grade 4 | 0 | 0 | 0 |
| Phosphorous — Not Reported | 6 | 0 | 1 |
| Albumin — Grade 0 | 15 | 15 | 15 |
| Albumin — Grade 1 | 13 | 4 | 14 |
| Albumin — Grade 2 | 6 | 2 | 12 |
| Albumin — Grade 3 | 0 | 0 | 1 |
| Albumin — Grade 4 | 0 | 0 | 0 |
| Albumin — Not Reported | 7 | 0 | 1 |
| Amylase — Grade 0 | 9 | 5 | 36 |
| Amylase — Grade 1 | 1 | 2 | 1 |
| Amylase — Grade 2 | 0 | 1 | 0 |
| Amylase — Grade 3 | 0 | 0 | 1 |
| Amylase — Grade 4 | 0 | 0 | 0 |
| Amylase — Not Reported | 31 | 13 | 5 |
| Lipase — Grade 0 | 15 | 6 | 31 |
| Lipase — Grade 1 | 1 | 1 | 5 |
| Lipase — Grade 2 | 0 | 1 | 1 |
| Lipase — Grade 3 | 0 | 0 | 3 |
| Lipase — Grade 4 | 0 | 0 | 1 |
| Lipase — Not Reported | 25 | 13 | 2 |
| Hypernatremia — Grade 0 | 35 | 20 | 42 |
| Hypernatremia — Grade 1 | 1 | 0 | 0 |
| Hypernatremia — Grade 2 | 0 | 0 | 0 |
| Hypernatremia — Grade 3 | 0 | 0 | 0 |
| Hypernatremia — Grade 4 | 0 | 0 | 0 |
| Hypernatremia — Not Reported | 5 | 1 | 1 |
| Hyponatremia — Grade 0 | 23 | 12 | 20 |
| Hyponatremia — Grade 1 | 12 | 7 | 15 |
| Hyponatremia — Grade 2 | 0 | 0 | 0 |
| Hyponatremia — Grade 3 | 1 | 1 | 7 |
| Hyponatremia — Grade 4 | 0 | 0 | 0 |
| Hyponatremia — Not Reported | 5 | 1 | 1 |
| Hyperkalemia — Grade 0 | 30 | 17 | 35 |
| Hyperkalemia — Grade 1 | 4 | 3 | 5 |
| Hyperkalemia — Grade 2 | 3 | 0 | 1 |
| Hyperkalemia — Grade 3 | 0 | 0 | 1 |
| Hyperkalemia — Grade 4 | 0 | 0 | 0 |
| Hyperkalemia — Not Reported | 4 | 1 | 1 |
| Hypokalemia — Grade 0 | 33 | 19 | 33 |
| Hypokalemia — Grade 1 | 4 | 1 | 6 |
| Hypokalemia — Grade 2 | 0 | 0 | 0 |
| Hypokalemia — Grade 3 | 0 | 0 | 3 |
| Hypokalemia — Grade 4 | 0 | 0 | 0 |
| Hypokalemia — Not Reported | 4 | 1 | 1 |
| Hypercalcemia — Grade 0 | 33 | 16 | 42 |
| Hypercalcemia — Grade 1 | 2 | 4 | 0 |
| Hypercalcemia — Grade 2 | 0 | 1 | 0 |
| Hypercalcemia — Grade 3 | 0 | 0 | 0 |
| Hypercalcemia — Grade 4 | 0 | 0 | 0 |
| Hypercalcemia — Not Reported | 6 | 0 | 1 |
| Hypocalcemia — Grade 0 | 25 | 14 | 15 |
| Hypocalcemia — Grade 1 | 8 | 7 | 21 |
| Hypocalcemia — Grade 2 | 2 | 0 | 6 |
| Hypocalcemia — Grade 3 | 0 | 0 | 0 |
| Hypocalcemia — Grade 4 | 0 | 0 | 0 |
| Hypocalcemia — Not Reported | 6 | 0 | 1 |
| Hypermagnesemia — Grade 0 | 34 | 21 | 40 |
| Hypermagnesemia — Grade 1 | 1 | 0 | 2 |
| Hypermagnesemia — Grade 2 | 0 | 0 | 0 |
| Hypermagnesemia — Grade 3 | 0 | 0 | 0 |
| Hypermagnesemia — Grade 4 | 0 | 0 | 0 |
| Hypermagnesemia — Not Reported | 6 | 0 | 1 |
| Hypomagnesemia — Grade 0 | 33 | 17 | 38 |
| Hypomagnesemia — Grade 1 | 2 | 4 | 4 |
| Hypomagnesemia — Grade 2 | 0 | 0 | 0 |
| Hypomagnesemia — Grade 3 | 0 | 0 | 0 |
| Hypomagnesemia — Grade 4 | 0 | 0 | 0 |
| Hypomagnesemia — Not Reported | 6 | 0 | 1 |
| Hyperglycemia — Grade 0 | 10 | 1 | 7 |
| Hyperglycemia — Grade 1 | 9 | 4 | 6 |
| Hyperglycemia — Grade 2 | 0 | 1 | 1 |
| Hyperglycemia — Grade 3 | 0 | 0 | 1 |
| Hyperglycemia — Grade 4 | 0 | 0 | 0 |
| Hyperglycemia — Not Reported | 22 | 15 | 28 |
| Hypoglycemia — Grade 0 | 19 | 6 | 14 |
| Hypoglycemia — Grade 1 | 0 | 0 | 1 |
| Hypoglycemia — Grade 2 | 0 | 0 | 1 |
| Hypoglycemia — Grade 3 | 0 | 0 | 0 |
| Hypoglycemia — Grade 4 | 0 | 0 | 0 |
| Hypoglycemia — Not Reported | 22 | 15 | 27 |
Collected over From first dose to 100 days post last dose (up to 36 months). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Nivolumab + Daratumumab (TNBC) | 29/41 (70.7%) | 36/41 (87.8%) | 40/41 (97.6%) |
| Nivolumab + Daratumumab (NSCLC) | 11/21 (52.4%) | 17/21 (81%) | 21/21 (100%) |
| Nivolumab + Daratumumab (PAC) | 36/43 (83.7%) | 36/43 (83.7%) | 41/43 (95.3%) |
| Event | Nivolumab + Daratumumab (TNBC) | Nivolumab + Daratumumab (NSCLC) | Nivolumab + Daratumumab (PAC) |
|---|---|---|---|
| Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 22/41 | 8/21 | 25/43 |
| Pleural effusionRespiratory, thoracic and mediastinal disorders | 8/41 | 0/21 | 1/43 |
| PneumoniaInfections and infestations | 1/41 | 2/21 | 0/43 |
| Respiratory tract infectionInfections and infestations | 0/41 | 2/21 | 0/43 |
| PyrexiaGeneral disorders | 2/41 | 1/21 | 4/43 |
| Abdominal painGastrointestinal disorders | 0/41 | 0/21 | 3/43 |
| AstheniaGeneral disorders | 2/41 | 0/21 | 1/43 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 2/41 | 0/21 | 2/43 |
| Acute coronary syndromeCardiac disorders | 0/41 | 1/21 | 0/43 |
| Pericardial effusionCardiac disorders | 0/41 | 1/21 | 0/43 |
| Event | Nivolumab + Daratumumab (TNBC) | Nivolumab + Daratumumab (NSCLC) | Nivolumab + Daratumumab (PAC) |
|---|---|---|---|
| AstheniaGeneral disorders | 12/41 | 12/21 | 11/43 |
| Infusion related reactionInjury, poisoning and procedural complications | 18/41 | 11/21 | 18/43 |
| Abdominal painGastrointestinal disorders | 8/41 | 4/21 | 19/43 |
| CoughRespiratory, thoracic and mediastinal disorders | 18/41 | 5/21 | 4/43 |
| ConstipationGastrointestinal disorders | 12/41 | 9/21 | 13/43 |
| DiarrhoeaGastrointestinal disorders | 9/41 | 9/21 | 17/43 |
| NauseaGastrointestinal disorders | 16/41 | 8/21 | 18/43 |
| Back painMusculoskeletal and connective tissue disorders | 8/41 | 8/21 | 3/43 |
| PruritusSkin and subcutaneous tissue disorders | 4/41 | 8/21 | 2/43 |
| Decreased appetiteMetabolism and nutrition disorders | 15/41 | 5/21 | 14/43 |
| Age, Continuous(Years) | Nivolumab + Daratumumab (TNBC) | Nivolumab + Daratumumab (NSCLC) | Nivolumab + Daratumumab (PAC) | Total |
|---|---|---|---|---|
| Mean | 55.1 ± 13.1 | 59.5 ± 8.5 | 61.9 ± 9.4 | 58.8 ± 11.2 |
| Sex: Female, Male(Participants) | Nivolumab + Daratumumab (TNBC) | Nivolumab + Daratumumab (NSCLC) | Nivolumab + Daratumumab (PAC) | Total |
|---|---|---|---|---|
| Female | 41 | 7 | 20 | 68 |
| Male | 0 | 14 | 23 | 37 |
| Ethnicity (NIH/OMB)(Participants) | Nivolumab + Daratumumab (TNBC) | Nivolumab + Daratumumab (NSCLC) | Nivolumab + Daratumumab (PAC) | Total |
|---|---|---|---|---|
| Hispanic or Latino | 1 | 0 | 0 | 1 |
| Not Hispanic or Latino | 20 | 3 | 21 | 44 |
| Unknown or Not Reported | 20 | 18 | 22 | 60 |
| Race/Ethnicity, Customized(Participants) | Nivolumab + Daratumumab (TNBC) | Nivolumab + Daratumumab (NSCLC) | Nivolumab + Daratumumab (PAC) | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 2 | 0 | 0 | 2 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 1 | 0 | 0 | 1 |
| White | 33 | 21 | 35 | 89 |
| Other | 5 | 0 | 8 | 13 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jun 2017 to primary completion in Jul 2020, 36 months.
Results were first posted in Jul 2021, 1 year after primary completion.
Of 309 industry-sponsored phase 1/2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 77. This study's 36 months is below that.
Counting every sponsor, half of 432 studies reached it within 63 months; a quarter within 42 and three quarters within 80.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Nivolumab
Carcinoma, Non-Small-Cell Lung →